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OVERVIEW   
  
  
Noncommunicable diseases are becoming increasing important in South Africa (SA).  
In particular, diseases of the circulatory system (including pulmonary embolism – PE) 
were responsible for over 2500 deaths in the country during 2007.  Although reports of 
PE from SA are rare, there are SA studies of deep vein thrombosis (of which PE is a 
complication) which suggest setting-specific risk factors for thromboembolic disease as 
well as certain risk factors reported in the overseas literature.  This might also hold true 
for PE.  Furthermore, there might be setting-specific risk factors for mortality in SA 
patients with PE.  A better description of PE in a SA setting would be useful in efforts 
to improve patient management and subsequent patient outcomes in this setting.    
 
The aim of this study was to improve the current understanding of PE in a SA setting.  
The objectives of this study were to: 1) Describe the presentation of PE in patients who 
were admitted to a tertiary SA hospital with the condition; 2) Determine the incidence 
of inpatient mortality in these patients; and 3) Determine which presenting 
characteristics are associated with inpatient mortality in SA patients with PE.   
 
This study was an analysis of data for 61 adult patients admitted to a tertiary SA 
hospital over a five-year period with a primary diagnosis of PE.  Data related to patient 
demographics, PE presentation, risk factors, treatment, and inpatient mortality were 
collected and analysed using appropriate statistical tests.  Overall, this study reports 
differences and similarities in certain aspects of the presentation and outcomes 
associated with PE between SA and overseas settings.  It is hoped that this research will 
lead to the generation of hypotheses which will improve PE management and 
subsequent patient outcomes in SA settings. 
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Part 1:  Literature review 
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1.1 Definition of pulmonary embolism: 
 
Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary 
embolism (PE).(1)  Pulmonary embolism is an uncommon but catastrophic complication 
of DVT during which a thrombus in the lower extremities fragments, forming emboli.  
These emboli migrate to the lung.(1-3) where they adversely affect pulmonary and 
cardiac function through disruption of the pulmonary circulation by occlusion.(3)  Where 
there is haemodynamic instability which can only be attributed to a PE, then a PE may 
be classified as massive.(4)  Submassive PE occurs when there is haemodynamic 
stability, but evidence of right ventricular dysfunction or myocardial necrosis.(4)  As 
with other conditions of the vascular system such as stroke and myocardial infarction, 
pulmonary embolism can be acute or chronic.(2)  
 
 
1.2 Pathophysiology of pulmonary embolism: 
 
The pathophysiology of PE begins with Virchow’s triad for VTE, namely: endothelial 
dysfunction/damage, hypercoagulability, and stasis (Figure 1).(3) These are the 
mechanisms through which DVT arises.(3)  As PE is a complication of DVT, Virchow’s 
triad also holds true for PE. 
 
 
Figure 1.  Virchow’s triad   
 
The migrating embolus can anatomically occlude the pulmonary circulation.(5)  This has 
three physiological consequences.  Firstly, there might be an increase in “dead space” 
(areas of lung where there is ventilation but no perfusion).(6,7)  The ratio of ventilation to 
perfusion is usually close to 1.0 (or balanced between ventilation and perfusion).(8)  An 
imbalance in this ratio is commonly referred to as a mismatch between the 
ventilation:perfusion ratio, or a V:Q mismatch.(8)  A V:Q mismatch is associated with 
arterial hypoxaemia.(9)  A PE might also cause vascular compromise, atelectasis, and 
subsequent V:Q mismatch.(9)  Lastly, there might be haemodynamic consequences 
resulting in potentially fatal heart failure, tachycardia, or hypotension.(7)  Chemical 
messengers such as serotonin are released into the circulation in response to an embolus.  
Serotonin can cause vasoconstriction, increased pulmonary resistance, and subsequent 
V:Q mismatch.(7)  Increased pulmonary resistance can also result in cardiovascular 
dysfunction (potentially fatal heart failure, tachycardia, or hypotension).  Histamine 
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released in response to a PE can induce bronchoconstriction, which leads to alveolar 
hypoxia and V:Q mismatch.(7)  An increase in respiratory rate is a compensatory 
response for hypoxaemia arising from the aforementioned V:Q mismatch.(9)  This 
manifests as the most common signs and symptoms of PE.(10)     
 
 
1.3 Incidence of pulmonary embolism: 
 
The incidence of VTE in various regions of the world has been summarized in a review 
document compiled by the 15th Steering Committee for World Thrombosis Day.(11)  The 
findings for PE have been extracted from the aforementioned review and are presented 
in Table 1, as incidence per 1000 people per year.  Data from Western Europe suggests 
that the incidence of PE in this region ranges between 0.15 and 0.95.(11)  The upper and 
lower range values for the incidence of PE in North America are much higher than those 
reported in the published literature for Western Europe.  The incidence of PE in the 
North American regions ranged from 0.45 (Canada) to 1.15 (United States).  There were 
only two published studies describing the incidence of PE in the Australasian region at 
the time, with both these studies emanating from Australia (incidence range: 0.31-
0.53).(11)  The incidence of PE in Asia (from two published studies) ranged between 
0.039 and 0.070.  There was only one published study from South America (Argentina) 
at the time the review was compiled, with the estimated incidence of PE falling within 
the ranges reported for Western Europe and North America.  There were no published 
studies identified as part of the review which specifically reported the incidence of PE 
in African countries.(11)   
  
Table I.  Incidence of pulmonary embolism around the world* 
Study Setting VTE incidence# PE incidence# 
 
Morreti et al. Italy Not reported 0.189 
Severinsen et al.  Denmark 1.15 0.51 
Cohen et al. France, Germany, Italy, Spain, Sweden, UK Not reported 0.95 
Heurta et al. UK 0.745 0.342 
Naess et al. Norway 1.43 0.50 
Guijjaro et al. Spain 0.036 0.15 
Oger et al. France 1.83 0.60 
Tagalakis et al. Canada 1.22 0.45 
Yusuf et al. US 2.39 1.15 
Weiner et al. US Not reported 1.12 
Cushman et al. US 1.61 0.45 
Stein et al. US 1.30 0.36 
Janke et al. US Not reported 0.60-0.90 
Silverstein et al. US 1.17 0.69 
Anderson et al. US 1.07 0.23 
Shiraev et al. Australia Not reported 0.53 
Ho et al. Australia 0.83 0.31 
Vazquez et al. Argentina 1.65 0.64 
Jang et al. Korea 0.138 0.070 
Cheuk et al. Hong Kong (China) Not reported 0.039 
*Extracted from a published review(11). 
#Incidence per 1000 people per year. 
VTE: Venous thromboembolism; PE: Pulmonary embolism, UK: United Kingdom, US: United States. 
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1.4 Risk factors for pulmonary embolism: 
 
In 2003, The British Thoracic Society published a guideline document for the 
management of PE which also provided an overview of risk factors associated with the 
condition.(12)  Risk factors for PE where classified as minor risk factors (risk factors 
with a relative risk of between 2.0 and 4.0) or major risk factors (risk factors with a 
relative risk of between 5.0 and 20.0).(12)  Minor risk factors were broadly categorized 
as cardiovascular (congenital heart disease, heart failure, hypertension, superficial 
venous thrombosis, indwelling central vein catheter), oestrogen use (oral contraceptives 
or hormone replacement therapy), and miscellaneous risk factors (chronic obstructive 
pulmonary disease, neurological disability, occult malignancy, thrombotic disorders, 
long distance travel, and obesity).(12)  Major risk factors identified in the guideline 
document included: Surgery (open abdominal/pelvic, hip/knee arthroplasty, 
postoperative critical care admission), obstetric factors (late pregnancy, caesarean 
section, puerperium), lower limb conditions (fracture, varicose veins), malignancy 
(abdominal/pelvic, advanced/metastatic disease), immobilization (due to hospitalization, 
institutional care), and previous VTE (DVT/PE).(12)   
 
A review by Kranidis et al., categorized risk factors for VTE as primary risk factors and 
secondary risk factors.(10)  Primary risk factors included: Factor V Leiden, antithrombin 
deficiency, resistance to activated protein C, hyperhomocysteinemia, prothrombin 
20210 mutation, antiphospholipid antibodies, protein C deficiency, and protein S 
deficiency.(10)  Most of the secondary risk factors were also cited in the British Thoracic 
Society guidelines,(12) with the exception of advanced age, diabetes, and smoking.(10)  
There is also evidence of HIV and tuberculosis infection as potential risk factor for PE 
in regions of the world where these infectious diseases are endemic.(13)  The importance 
of these risk factors cannot be ignored and some of these are components of risk 
stratification methods for PE.  
 
 
1.5 Mortality associated with pulmonary embolism: 
 
Mortality is the most severe outcome of PE.  There are a few studies which report 90 
day mortality rates in outpatients with PE, or mortality rates for patient admitted to 
hospital with a primary diagnosis of PE.(2)  The International Cooperative Pulmonary 
Embolism Registry (N=2454) reported the 90 day all-cause mortality rate in registry 
patients to be 17%.(2,14)  An American study conducted in Massachusetts reported the 90 
day all-cause mortality rate in outpatients with PE to be 11%.(2,15)  Analysis of the 
Registry of Patients with Venous Thromboembolism (N=6264) reported a lower 90 day 
all-cause mortality rate of 8.6%.(2,16)   In fact, PE might account for up to 10% of all 
inpatient deaths.5   
 
Most estimates of mortality in patients admitted to hospital with PE come from sub-
analyses of large, administrative datasets.  A sub-analysis of 34108 PE admissions from 
the 2012 American Healthcare Cost and Utilization Project National Inpatient Sample, 
found the overall inpatient mortality rate to be 3.4%.(17)  An analysis of another 
American hospital administrative database, the Nationwide Inpatient Sample, reported 
mortality rates of between 3.2% and 7.1 % in patients admitted with PE over a 10-year 
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period.(18)  A study of Portuguese hospital admissions with PE between 2003 and 2013 
(N=35200) reported in-hospital mortality rates of between 11.2% and 25%.(19)  The 
mortality rates of patients with untreated PE have been described as much higher than 
those reported for patients where PE has been treated.(10)  However, appropriate 
treatment can only be initiated once a diagnosis of PE is made.  This highlights the 
importance of effective diagnostic management in patients where PE is suspected.   
 
 
1.6 Signs and symptoms of pulmonary embolism: 
 
The signs and symptoms of PE vary considerably.  In their published review, Kranidis 
et al., listed some of the common signs and symptoms associated with PE.(10)  
Tachypnea, or an increased respiratory rate (>20 breaths per minute), is the most 
common sign and is reported in up to 70% of patients with PE.(10)  Tachycardia (a heart 
rate >100 beats/minute) is reported in 26% of patients with PE.  Signs of DVT, such as 
lower limb pain or swelling, is reported in 15% or patients.  Cyanosis (discolouration of 
the skin, nails, and mucosa) is observed in 11% of patients with PE.  Pyrexia 
(temperature of >38oC) might be present in 7% of patients.(10)   
 
Dyspnoea (shortness of breath) is the most common symptom reported in patients with 
PE (up to 80% of patients with PE).(10)  Chest pain is another common symptom.  There 
are two types of chest pain reported in patients with PE, namely pleuritic chest pain (in 
up to 52% of patients) and substernal chest pain (in up to 12% of patients).  Up to 20% 
of patients with PE might present with cough.(10)  Haemoptysis (expectoration of blood 
originating from the tracheobronchial tree or pulmonary parenchyma) is reported in 
11% of patients.  Approximately 19% of patients with PE reported a history of recent 
syncope (abrupt loss of consciousness with a concomitant loss of postural tone) or its 
prodrome (presyncope).(10)  Cardiac enzyme measurements, such as troponins, might 
also be elevated in patients with PE and have been associated with increased 
mortality.(20)  This is likely the result of cardiac dysfunction modulated by PE.(7)   
 
 
1.7 Diagnostic and therapeutic management of pulmonary embolism: 
 
The varying clinical presentation of PE and the overlap of some signs and symptoms 
with that of cardiac disease pose a considerable diagnostic challenge.(10)  Therefore a 
diagnosis of PE is unlikely to be made based solely on clinical presentation.  Goolam-
Mahomed has provided a diagnostic algorithm for PE in South African settings (Figure 
2).(21)  The first step of the algorithm involves assessing the probability of PE.  This is 
commonly done using tools such as the Well’s Score (Table 2),(22) although there are 
other scoring systems which can also be used (the Geneva Score or the Pisa Score).(23,24)  
These scoring systems are based on the presence of certain clinical signs, symptoms, 
and risk factors which are each allocated a weighted point score.  Total point scores can 
then be used to stratify if a patient has a low, intermediate, or high probability of PE.(22-
24) 
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Figure 2.  Algorithm for the diagnosis of pulmonary embolism* 
*From: Goolam-Mahomed (2013)(21) 
 
 
Table II.  The Well’s Score* 
*From: Wells et al. (1998)(22) 
 
Patients with a high probability of PE are required to undergo computed tomography 
pulmonary angiography (CTPA).(21)  This imaging modality involves the use of 
computed tomography to visualize the pulmonary arteries and any filling defects.  The 
Clinical feature Points 
Clinical signs and symptoms of DVT  3 
An alternative diagnosis is less likely than PE 3 
Heart rate > 100 beats per minute 1.5 
Immobilisation for more than 3 days or surgery in the previous 4 weeks 1.5 
Previous DVT/PE 1.5 
Haemoptysis 1 
Malignancy (on treatment, treated in the last 6 months, or palliative) 1 
7  
  
sensitivity and specificity of CTPA for PE is impressive (sensitivity of 83-100% and 
specificity of 89-96%).(25)  Patients with a low or intermediate probability of PE are 
required to undergo d-dimer measurements.(21)  D-dimers are cross-linked fibrin 
degradation products following fibrinolysis of a thromboembolism.(26)  Any d-dimer 
measurement of 500μg/L or higher is considered potentially indicative of PE and 
requires further investigation with CTPA.(21)  Causes of symptoms, other than PE, 
should be investigated in patients with d-dimer measurements of <500μg/L.  This step is 
also applicable in patients with no findings suggestive of PE on CTPA.  Patients with 
findings suggestive of PE on CTPA should be offered treatment for PE.(21)   
 
Treatment options for PE include: Anticoagulation, thrombolysis, and embolectomy.(27-
29)  Anticoagulation is the primary choice of therapy for PE.(2)  Anticoagulation agents 
can be intravenous (such as unfractionated heparin, or low weight molecular heparin 
agents such as enoxaparin) or oral anticoagulation agents (the most widely used being 
warfarin).(27)  Antithrombin III (AT3) inhibits several activated clotting factors.  
Therefore, drugs which augment the function of AT3 serve as anticoagulants.(27)  
Heparin is known to increase the activity of AT3.  Warfarin inhibits the activities of the 
enzyme vitamin K-epoxide reductase, which produces the active form of the vitamin K-
dependent clotting factors.(27)  A randomized controlled study by Barritt et al., provided 
the first evidence suggesting that there was reduced mortality associated with 
anticoagulation therapy in patients with PE.(30)  Several studies since then have 
confirmed the benefits of anticoagulation therapy in patients with PE.(31-33)  However, 
haemorrhage is a possible adverse event associated with anticoagulation therapy.(27)       
 
Thrombolytic agents are based on fibrinolytic substances produced by streptococci 
bacteria.(34)  The most well-known of these agents is streptokinase, which is also used in 
the treatment of acute myocardial infarction.(28,34)  Thrombolysis is indicated in 
situations of massive PE with hypotension or systemic hypoperfusion, right ventricular 
dysfunction, pulmonary hypertension, extensive DVT, and prevention of recurrent 
PE.(35)  Important drawbacks of thrombolytic agents include allergic reactions, 
hypotension, reperfusion arrhythmias, and haemorrhage.(35)   As such, thrombolysis is 
contraindicated in patients with a high risk of haemorrhage, recent major 
surgery/trauma, gastrointestinal bleeding, central nervous system neoplasm or known 
bleeding diathesis.(35)   A Cochrane Systematic Review reported that there was low 
quality evidence supporting a reduction in mortality in patients with acute PE receiving 
thrombolytic therapy when compared with heparin.(36)  Furthermore, the same 
systematic review reported that while thrombolytic therapy might be helpful in reducing 
recurrent PE, it may cause more haemorrhagic events and stroke.(36)  Therefore, 
thrombolysis should be used only when clinically indicated.    
 
Pulmonary embolectomy, through which a PE is removed through an open thoracic 
surgery procedure, is performed in patients where thrombolysis is contraindicated or 
unsuccessful.(29,35)  It is therefore an important management option in patients with 
advanced PE.(29,35)  Although the procedure was initially associated with high levels of 
mortality,(29) a collective review of cases suggests that there has been a decreasing trend 
in mortality associated with pulmonary embolectomy (32% before 1985 versus 20% in 
the period between 1985 and 2005).(37)  Nevertheless, the mortality associated with this 
procedure still remains high and there should be careful consideration on the part of 
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physicians and surgeons when deciding to perform the procedure.       
 
 
1.8 Gap in the literature: 
 
Published descriptions of PE in African settings are rare.(11)  Many African countries 
(including South Africa) are undergoing an “epidemiological transition”,(38-40) whereby 
the burden of noncommunicable disease, including VTE (DVT and PE) and some of its 
risk factors, are approaching levels similar to that of communicable disease which has 
traditionally accounted for most of the morbidity and mortality on the continent.  A 
better understanding of PE in an African setting would contribute towards improving 
patient care for PE in this setting.     
 
 
1.9 Problem statement: 
 
South Africa is currently experiencing an epidemiological transition, whereby the 
national noncommunicable disease burden is approaching that of communicable 
disease.(38-41)   Non-communicable diseases comprised 60% of the ten leading 
underlying natural causes of death in South Africa for 2015.(42)  While no specific data 
is available for PE, a 2007 report found 2566 deaths in the country could be attributed to 
diseases of the circulatory system, a composite measure which includes PE, stroke, and 
myocardial infarction.(21)  Interestingly, embolic pathophysiology also appears to play 
some role in stroke and myocardial infarction.(43,44)   
 
However, descriptions of PE in South African settings are rare.  Recent evidence from a 
study of DVT in a South African setting suggest that there are some setting-specific risk 
factors for VTE, most notably HIV infection and tuberculosis.(13)  It is also possible that 
there might be some discordancy between other clinical/laboratory presentation and risk 
factors for PE between South African settings and European/American settings, 
however this is yet to be demonstrated.  It might also be possible that there are 
differences in mortality between South African and overseas patients with PE.  A better 
description of PE in a South African setting would be useful in efforts to improve 
patient management and subsequent patient outcomes in this setting.    
 
 
1.10 Aim: 
 
The aim of this study was to improve the current understanding of PE in a South 
African setting. 
 
 
1.11 Objectives: 
 
The objectives of this study were to 
1. Describe the presentation of PE in patients who were admitted to a tertiary South 
African hospital with the condition (the study population) 
2. Determine the incidence of mortality in the study population 
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3. Determine which presenting characteristics are associated with inpatient mortality in 
the study population   
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ABSTRACT 
 
Background:  Published descriptions of pulmonary embolism (PE) from South African 
(SA) settings are rare.  We sought to address this gap in the literature. 
Methods:  This was a case series involving 61 adult patients admitted to a tertiary SA 
hospital over a five-year period with a primary diagnosis of PE.  Data related to patient 
demographics, PE presentation, risk factors, treatment, and inpatient mortality were 
collected and analysed using appropriate statistical tests.  
Results:  Most of our study population were younger (86.9%), female (67.2%), and of 
black African ethnicity (73.8%).  Dyspnoea and chest pain were the most common 
symptoms (prevalence of 86.9% and 41.0%).  Prevalent clinical signs included 
tachypnea (47.5%) and tachycardia (42.6%).  The most prevalent established risk 
factors were cardiac failure (49.2%) and a history of deep vein thrombosis (up to 
19.7%).  Massive PE was diagnosed in 8.2% of study patients.  Most patients received 
anticoagulation therapy (95.1%), with thrombolysis and embolectomy performed only 
in smaller proportions (24.6% and 11.5%) of patients.  The incidence of inpatient 
mortality was 23.0%.  Characteristics associated with mortality included: admission 
route (p=0.008), dyspnoea (p=0.002), tachycardia (p<0.001), and embolectomy 
(p=0.042).   
Conclusion:  Our study findings have important implications related to the management 
of PE in SA.  
 
 
Keywords:  Pulmonary embolism; South Africa; Clinical presentation; Risk factors; 
Mortality.  
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INTRODUCTION 
 
Pulmonary embolism (PE) is an important complication of deep vein thrombosis 
(DVT).(1)  Both PE and DVT are manifestations of venous thromboembolism (VTE).  
An incidence rate of nearly 1.0 case per 1000 people has been reported for PE in North 
American/European settings.(2)  Mortality is much higher in patients with undiagnosed, 
untreated PE. Therefore, a better understanding of the presentation of PE is required 
such that patients can be diagnosed timeously and treatment can be initiated.(3)  
However, the presentation of PE itself is highly variable and can pose diagnostic 
challenges.(2-4)  While there are no specific data available for PE in a South African 
(SA) setting, a 2007 report found 2566 deaths in the country could be attributed to 
diseases of the circulatory system, a composite measure which includes PE, stroke, and 
myocardial infarction.(5)  Interestingly, embolic pathophysiology also appears to play 
some role in stroke and myocardial infarction.(6,7)  While descriptions of PE in SA 
settings are rare, recent evidence from a study of DVT in a SA setting suggest that there 
might be some setting-specific differences in the characteristics and risk factors for VTE 
between SA and overseas settings.(8)  It is possible that there might be some discordancy 
between the characteristics, risk factors, and mortality associated with PE between SA 
settings and overseas settings.  However, this is yet to be demonstrated.  A better 
description of PE in a SA setting would be useful in efforts to improve patient 
management and subsequent patient outcomes in this setting.   Therefore, the aim of this 
study was to improve the current understanding of PE in a SA setting.  The objectives of 
this study were to 1) Describe the presentation/characteristics of PE in patients who 
were admitted to a tertiary SA hospital with the condition (the study population - SP); 2) 
Determine the incidence of mortality in the SP; 3) Determine which characteristics are 
associated with inpatient mortality in the SP; and 4) Discuss similarities and differences 
related to PE between SA and overseas settings.   
 
 
MATERIALS AND METHODS 
 
Study design, study setting, and study population:  
 
This was a retrospective case series of 61 adult patients who were admitted with a 
primary diagnosis of PE to the tertiary-level Inkosi Albert Luthuli Central Hospital 
(IALCH) in Durban, South Africa over a five-year period (01 January 2011 to 31 
December 2015).  These patients were identified using the hospital admissions database 
and the International Classification of Diseases 10th Revision (ICD-10) code I26 
(includes I26.0, I26.9, and sub-categories thereof).  Furthermore, PE was confirmed 
through review of patient computed tomography reports.  Patients aged <18 years old, 
repeat admissions for PE, and patients admitted outside the specified study period were 
excluded from this study.   
 
Data collection: 
 
The medical records of all patients included in this study were reviewed and 
information related to patient demographics, clinical presentation, potential risk factors, 
classification and treatment of PE, and inpatient mortality were collected using a paper-
16  
  
based data collection tool.  The data were then transferred to an electronic spreadsheet 
in preparation for statistical analyses.   
 
Statistical analysis: 
 
We initially analysed our data using descriptive statistical methods.  Results for the 
descriptive statistical analysis are presented as frequencies and percentages.  We 
calculated the incidence of inpatient mortality in our SP using conventional 
epidemiological methods, and present this as a percentage with a 95% confidence 
interval (95% CI).  We also tested for the presence of crude statistical associations 
between various characteristics and inpatient mortality using chi-squared or Fisher’s 
tests.  Results for this component of the statistical analysis are presented as frequencies 
and percentages, with a corresponding p-value.  A p-value <0.050 was considered a 
statistically significant result.  All statistical analyses were performed using the 
Statistical Package for the Social Sciences version 24.0 (IBM Corp, USA).    
 
Study ethical approval: 
 
This study received ethical approval from the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BE589/17). 
 
 
RESULTS 
 
Description of the SP: 
 
Demographic profile of the SP: 
The demographic profile of the SP is presented in Table I.  Most patients in our SP were 
<65 years old (n/N=53/61, 86.9%).  Just over two-thirds of the SP were female 
(n/N=41/61, 67.2%).  Approximately three-quarters of the SP were of black African 
ethnicity (n/N=45/61, 73.8%).  Almost one-third of the SP was admitted through the 
emergency department/critical care unit (n/N=20/61, 32.8%). 
 
Distribution of PE clinical symptoms and signs in the SP: 
A description of PE clinical symptoms and signs in the SP is shown in Table I.  A large 
proportion of the SP did not report any chest pain on admission to hospital (n/N=36/61, 
59.0%), while pleuritic chest pain and substernal chest pain were reported in 24.6% 
(n/N=15/61) and 16.4% (n/N=10/61) of the SP.  Dyspnoea on admission was common 
(86.9% of the SP, n/N=53/61), with 24.6% (n/N=15/61) of study patients reporting 
dyspnoea of ≥NYHA grade III, 6.6% (n/N=4/61) of study patients reporting dyspnoea 
of <NYHA grade III, and 55.7% (n/N=34/61) of study patients experiencing dyspnoea 
of unreported grade.  Just over one-third of the SP presented with cough (n/N=23/61, 
37.7%).  Haemoptysis was reported in a total of 16.4% (n/N=10/61) of the SP.  
Haemoptysis was reported as major in 3.3% (n/N=2/61) of the SP and minor in 4.9% 
(n/N=3/61) of the SP.  The severity of haemoptysis could not be established from the 
medical records of five study patients (8.2% of the SP) who presented with 
haemoptysis.  Approximately 15.0% of the SP experienced syncopal events prior to 
hospital admission (4.9% with syncope and 9.8% with presyncope).  Just under half the 
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SP presented to hospital with tachypnea (n/N=29/61, 47.5%).  Similarly, just under half 
the SP presented to hospital with tachycardia (n/N=26/61, 42.6%).  Cyanosis and 
pyrexia were reported in 4.9% (n/N=3/61) and 3.3% (n/N=2/61) of the SP.  Just over a 
third of the SP presented to hospital with lower limb swelling or pain (n/N=23/61, 
37.7%).  One in every four patients presented with abnormal O2 saturation 
measurements (n/N=17/61, 27.9%).  One-third of the SP presented with abnormal pO2 
measurements (n=21/61, 34.4%), 4.9% (n/N=3/61) presented with normal pO2 
measurements, and pO2 measurements could not be established for the remainder of the 
SP (n/N=37, 60.7%).  Half the SP received supplemental oxygen on admission 
(n/N=31/61, 50.8%).  Five study patients (8.2% of the SP) required mechanical 
ventilation.  Most of the SP was normotensive (n/N=45/51, 73.8%), while hypotension 
and hypertension was reported in 8.2% (n/N=5/61) and 18.0% (n/N=11/61) of the SP.  
Half of the patients in the SP (n/N= 31/61, 50.8%) had elevated D-dimer measurements, 
4.9% (n/N=3/61) had normal D-dimer measurements, while the results of D-dimer tests 
were not reported for 37 patients (44.3% of the SP).  Approximately one-quarter of the 
SP had elevated cardiac enzyme measurements on admission to hospital (n/N=14/61, 
23.0%).  Cardiac enzyme measurements were normal or not reported in 39.3% 
(n/N=24/61) and 37.7% (n/N=23/61) of the SP, respectively.   
 
Prevalence of PE risk factors in the SP: 
The distribution of PE risk factors in the SP is shown in Table I.  Half of the SP 
presented to hospital with cardiac failure (n/N=30/61, 49.2%).  Only two patients 
(3.3%) had a history of stroke.  Eight patients (13.1%) reported recent immobilization.  
Two patients (3.3%) reported recent long-distance travel.  Around one in every six 
patients in the SP (16.4%) had recently undergone surgical procedures.  Malignancy 
was present in 3.3% of the SP (n/N=2/61, one patient with lymphoma and one patient 
with solid tumour).  One in every ten study patients reported tobacco use (n/N=6/61, 
9.8%).  A prior history of PE was reported in 8.2% of the SP (n/N=5/61).  A prior 
history of DVT was reported in 11.5% of patients (n/N=7/61).  One in five study 
patients presented with concurrent DVT (n/N=12/61, 19.7%).  No patients in the SP 
were pregnant.  One patient (1.6% of the SP) was on hormonal therapy/contraception.  
Obesity was noted in 17 patients (27.9% of the SP), while 14 patients (23.0% of the SP) 
were not obese.  Body mass index could not be calculated for 49.1% of the SP 
(n/N=30/61).  Seventeen patients had HIV infection (27.9% of the SP).  Eight patients 
(13.1 of the SP) reported a prior history of tuberculosis.  Three patients (4.9% of the SP) 
had current tuberculosis infection.   
 
Classification of and treatment of PE in the SP: 
Five patients (8.2% of the SP) presented with a massive PE (Table I).  Almost two-
thirds of the SP (62.3% of patients) presented with submassive PE, while 8.2% of the 
SP (n/N=5/61) presented with minor PE.  We were unable to classify PE in the 
remaining 21.3% of the SP (n/N=13/61) as the relevant information (either cardiac 
enzyme measurements or cardiac function investigations) was not reported in the patient 
medical records.  Data related to the treatment of PE in our SP is also presented in Table 
I.  Almost all patients in the SP received anticoagulation therapy (n/N=58/61, 95.1%).  
Embolectomy was performed in 11.5% of the SP (n/N=7/61).  Thrombolysis was 
performed in a quarter of the SP (n/N=15/61, 24.6%).    
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Table I.  Description of the SP (N=61) 
Characteristic Sub-category n (% of N) 
 
Elderly age (Age ≥65 years old) Yes 8 (13.1) 
 No 53 (86.9) 
Gender Male 20 (32.8) 
 Female 41 (67.2) 
African ethnicity Yes 45 (73.8) 
 No 16 (26.2) 
Admitted via ED/CCU Yes 20 (32.8) 
 No 41 (67.2) 
Chest pain Yes, pleuritic 15 (24.6) 
 Yes, substernal 10 (16.4) 
 No 36 (59.0) 
Dyspnoea Yes, ≥ NYHA grade III 15 (24.6) 
 Yes, < NYHA grade III 4 (6.6) 
 Yes, grade not reported 34 (55.7) 
 No 8 (13.1) 
Cough Yes 23 (37.7) 
 No 38 (62.3) 
Haemoptysis Yes, major 2 (3.3) 
 Yes, minor 3 (4.9) 
 Yes, not reported 5 (8.2) 
 No 51 (83.6) 
Syncopal events Yes, syncope 3 (4.9) 
 Yes, presyncope 6 (9.8) 
 No 52 (85.3) 
Tachypnea  
(Respiratory rate >20 breaths/min) 
Yes 29 (47.5) 
 No 32 (52.5) 
Tachycardia (Heart rate >100 beats/min) Yes 26 (42.6) 
 No 35 (57.4) 
Cyanosis Yes 3 (4.9) 
 No 58 (95.1) 
Pyrexia (Temperature >38.5oC) Yes 2 (3.3) 
 No 59 (96.7) 
Lower limb swelling/pain Yes 23 (37.7) 
 No 38 (62.3) 
O2 saturation (as per pulse oximetry) ≤95% 17 (27.9) 
 >95% 44 (72.1) 
Abnormal pO2 (pO2 outside 80-100 mmHg) Yes 21 (34.4) 
 No 3 (4.9) 
 Not reported 37 (60.7) 
Supplemental O2 Yes 31 (50.8) 
 No 30 (49.2) 
Mechanical ventilation Yes 5 (8.2) 
 No 56 (91.8) 
Systolic blood pressure on admission Hypotensive (≤90 mmHg) 5 (8.2) 
 Normotensive  
(91-139 mmHg) 
45 (73.8) 
 Hypertensive  
(≥140 mmHg) 
11 (18.0) 
D-dimer >99th percentile URL 31 (50.8) 
 ≤99th percentile URL 3 (4.9) 
 Not reported 37 (44.3) 
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Troponin >99th percentile URL 14 (23.0) 
 ≤99th percentile URL 24 (39.3) 
 Not reported 23 (37.7) 
Cardiac failure Yes 30 (49.2) 
 No 31 (50.8) 
Stroke Yes 2 (3.3) 
 No 59 (96.7) 
Recent immobilization* Yes 8 (13.1) 
 No 53 (86.9) 
Recent long-distance travel** Yes 2 (3.3) 
 No 59 (96.7) 
Recent surgery*  Yes 10 (16.4) 
 No 51 (83.6) 
Recent trauma* Yes 2 (3.3) 
 No 59 (96.7) 
Malignancy (Solid tumour or Haematological) Yes 2 (3.3) 
 No 59 (96.7) 
Tobacco use Yes 6 (9.8) 
 No 55 (90.2) 
Prior PE Yes 5 (8.2) 
 No 56 (91.8) 
Prior DVT Yes 7 (11.5) 
 No 54 (88.5) 
Current DVT Yes 12 (19.7) 
 No 49 (80.3) 
Pregnancy Yes 0 (0.0) 
 No 61 (100.0) 
Hormonal therapy/contraception Yes 1 (1.6) 
 No 60 (98.4) 
Obesity (Body mass index >30 kg/m2) Yes 17 (27.9) 
 No 14 (23.0) 
 Not reported 30 (49.1) 
HIV Yes 17 (27.9) 
 No 44 (72.1) 
Prior tuberculosis Yes 8 (13.1) 
 No 53 (86.9) 
Current tuberculosis Yes 3 (4.9) 
 No 58 (95.1) 
PE classification# Massive 5 (8.2) 
 Submassive 38 (62.3) 
 Minor 5 (8.2) 
 Not reported 13 (21.3) 
Embolectomy Yes 7 (11.5) 
 No 54 (88.5) 
Thrombolysis Yes 15 (24.6) 
 No 46 (75.4) 
Anticoagulation Yes 58 (95.1) 
 No 3 (4.9) 
SP: Study population; N/A: Not applicable; ED: Emergency department; CCU: Critical care unit; NYHA: 
New York Heart Association; URL: Upper reference limit; PE: Pulmonary embolism; DVT: Deep vein 
thrombosis.  
*Within the last 4 weeks; **Duration >4 hours within the last 4 weeks; #As per reference 26. 
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Mortality in the SP: 
 
Incidence of mortality in the SP: 
Figure 1 shows the inpatient survival outcomes of the SP.  Of the 61 patients in the SP, 
14 suffered inpatient mortality (Incidence of 23.0%, 95% CI: 13.2-35.5%). Of the 14 
patients who suffered inpatient mortality, the distribution of the classes of PE is as 
illustrated in Figure 1.   
 
 
Figure 1.  Inpatient survival outcomes 
PE: Pulmonary embolism 
 
 
Statistical comparisons between various characteristics and inpatient mortality in the 
SP:  
Statistical comparisons between various characteristics and inpatient mortality in our SP 
are shown in Table II.  Statistically significant crude associations (p<0.050) were noted 
between several characteristics/variables investigated in this study and inpatient 
mortality.  A higher proportion of patients admitted through the emergency 
department/critical care unit suffered inpatient mortality when compared to patients who 
were admitted via alternative departments (64.3% versus 23.4%, p=0.008).  Dyspnoea 
was also found to be statistically associated with inpatient mortality (p=0.002).  Of note, 
the proportion of patients with dyspnoea of NYHA grade III or more was higher in 
patients who died versus patients who did not die (42.9% versus 19.1%).  The 
proportion of patients with tachycardia was higher in the mortality group when 
compared to the no-mortality group (85.7% versus 29.8%, p<0.001).  Lastly, the 
proportion of patients who underwent embolectomy was higher in the mortality group 
when compared to the no-mortality group (28.6% versus 6.4%, p=0.042).  We did not 
find statistically significant associations between the remaining characteristics 
investigated in this study and inpatient mortality.   
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Table II.  Statistical comparisons between characteristics in the SP and inpatient 
mortality 
Characteristic Sub-category No mortality 
(n=47) 
Mortality 
(n=14) 
 
 
p-value 
 
 
Elderly age (Age ≥65 years old)    0.999 
 Yes 6 (12.8) 2 (14.3)  
 No 41 (87.2) 12 (85.7)  
Gender    0.116 
 Male 18 (38.3) 2 (14.3)  
 Female 29 (61.7) 12 (85.7)  
African ethnicity    0.490 
 Yes 36 (76.6) 9 (64.3)  
 No 11 (23.4) 5 (35.7)  
Admitted via ED/CCU    0.008 
 Yes 11 (23.4) 9 (64.3)  
 No 36 (76.6) 5 (35.7)  
Chest pain    0.914 
 Yes, pleuritic 11 (23.4) 4 (28.6)  
 Yes, substernal 8 (17.0) 2 (14.3)  
 No 28 (59.6) 8 (57.1)  
Dyspnoea    0.002 
 Yes, ≥ NYHA grade III 9 (19.1) 6 (42.9)  
 Yes, < NYHA grade III 4 (8.5) 0 (0.0)  
 Yes, grade not reported 31 (66.0) 3 (21.4)  
 No 3 (6.4) 5 (35.7)  
Cough    0.999 
 Yes 18 (38.3) 5 (35.7)  
 No 29 (61.7) 9 (64.3)  
Haemoptysis    0.647 
 Yes, major 1 (2.1) 1 (7.1)  
 Yes, minor 2 (4.3) 1 (7.1)  
 Yes, not reported 4 (8.5) 1 (7.1)  
 No 40 (85.1) 11 (78.7)  
Syncopal events    0.666 
 Yes, syncope 3 (6.4) 0 (0.0)  
 Yes, presyncope 4 (8.5) 2 (14.3)  
 No 40 (85.1) 12 (85.7)  
Tachypnea (Respiratory rate >20 
breaths/min) 
   0.153 
 Yes 20 (42.6) 9 (64.3)  
 No 27 (57.4) 5 (35.7)  
Tachycardia (Heart rate >100 
beats/min) 
   <0.001 
 Yes 14 (29.8) 12 (85.7)  
 No 33 (70.2) 2 (14.3)  
Cyanosis    0.999 
 Yes 3 (6.4) 0 (0.0)  
 No 44 (93.6) 14 (100.0)  
Pyrexia (Temperature >38.5oC)    0.409 
 Yes 1 (2.1) 1 (7.1)  
 No 46 (97.9) 13 (92.9)  
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Lower limb swelling/pain    0.999 
 Yes 18 (38.3) 5 (35.7)  
 No 29 (61.7) 9 (64.3)  
O2 saturation (as per pulse 
oximetry) 
   0.506 
 ≤95% 12 (25.5) 5 (35.7)  
 >95% 35 (74.5) 9 (64.3)  
Abnormal pO2 (pO2 outside 80-
100 mmHg) 
   0.498 
 Yes 15 (31.9) 6 (42.9)  
 No 2 (4.3) 1 (7.1)  
 Not reported 30 (63.8) 7 (50.0)  
Supplemental O2    0.079 
 Yes 21 (44.7) 10 (71.4)  
 No 26 (55.3) 4 (28.6)  
Mechanical ventilation    0.074 
 Yes 2 (4.3) 3 (21.4)  
 No 45 (95.7) 11 (78.6)  
Systolic blood pressure on 
admission 
   0.151 
 Hypotensive (≤90 
mmHg) 
2 (4.3) 3 (21.4)  
 Normotensive (91-139 
mmHg) 
36 (76.6) 9 (64.3)  
 Hypertensive (≥140 
mmHg) 
9 (19.1) 2 (14.3)  
D-dimer    0.999 
 >99th percentile URL 24 (51.1) 7 (50.0)  
 ≤99th percentile URL 2 (4.3) 1 (7.1)  
 Not reported 21 (44.7) 6 (42.9)  
Troponin    0.857 
 >99th percentile URL 10 (21.3) 4 (28.6)  
 ≤99th percentile URL 19 (40.4) 5 (35.7)  
 Not reported 18 (38.3) 5 (35.7)  
Cardiac failure    0.999 
 Yes 23 (48.9) 7 (50.0)  
 No 24 (51.1) 7 (50.0)  
Stroke    0.999 
 Yes 2 (4.3) 0 (0.0)  
 No 45 (95.7) 14 (100.0)  
Recent immobilization*    0.668 
 Yes 7 (14.9) 1 (7.1)  
 No 40 (85.1) 13 (92.9)  
Recent long-distance travel**    0.999 
 Yes 2 (4.3) 0 (0.0)  
 No 45 (95.7) 14 (100.0)  
Recent surgery*    0.999 
 Yes 8 (17.0) 2 (14.3)  
 No 39 (83.0) 12 (85.7)  
Recent trauma*    0.999 
 Yes 2 (4.3) 0 (0.0)  
 No 45 (95.7) 14 (100.0)  
Malignancy (Solid tumour or 
Haematological) 
   0.050 
 Yes 0 (0.0) 2 (14.3)  
 No 47 (100.0) 12 (96.7)  
23  
  
Tobacco use    0.321 
 Yes 6 (12.8) 0 (0.0)  
 No 41 (87.2) 14 (100.0)  
Prior PE    0.999 
 Yes 4 (8.5) 1 (7.1)  
 No 
 
43 (91.5) 13 (92.9)  
Prior DVT    0.999 
 Yes 6 (12.8) 1 (7.1)  
 No 41 (87.2) 13 (92.9)  
Current DVT    0.999 
 Yes 9 (19.1) 3 (21.4)  
 No 38 (80.9) 11 (78.6)  
Pregnancy    UC 
 Yes 0 (0.0) 0 (0.0)  
 No 47 (100.0) 14 (100.0)  
Hormonal therapy/contraception    0.999 
 Yes 1 (2.1) 0 (0.0)  
 No 46 (97.9) 14 (100.0)  
Obesity (Body mass index >30 
kg/m2) 
   0.674 
 Yes 13 (27.7) 4 (28.6)  
 No 12 (25.5) 2 (14.3)  
 Not reported 22 (46.8) 8 (57.1)  
HIV    0.311 
 Yes 15 (31.9) 2 (14.3)  
 No 32 (68.1) 12 (85.7)  
Prior tuberculosis    0.180 
 Yes 8 (17.0) 0 (0.0)  
 No 39 (83.0) 14 (0.0)  
Current tuberculosis    0.549 
 Yes 2 (4.3) 1 (7.1)  
 No 45 (95.7) 13 (92.9)  
PE classification#    0.167 
 Massive 2 (4.3) 3 (21.4)  
 Submassive 30 (63.8) 8 (57.1)  
 Minor 5 (10.6) 0 (0.0)  
 Not reported 10 (21.3) 3 (21.4)  
Embolectomy    0.042 
 Yes 3 (6.4) 4 (28.6)  
 No 44 (93.6) 10 (71.4)  
Thrombolysis    0.483 
 Yes 13 (27.7) 2 (14.3)  
 No 34 (72.3) 12 (85.7)  
Anticoagulation    0.129 
 Yes 46 (97.9) 12 (85.7)  
 No 1 (2.1) 2 (14.3)  
N/A: Not applicable; ED: Emergency department; CCU: Critical care unit; NYHA: New York Heart 
Association; URL: Upper reference limit; PE: Pulmonary embolism; DVT: Deep vein thrombosis.  
*Within the last 4 weeks; **Duration >4 hours within the last 4 weeks; #As per reference 26. 
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DISCUSSION 
 
Importance of our study: 
 
We provide a report of patients admitted to a tertiary SA hospital with a primary 
diagnosis of PE.  Our study is important as it is, to the best of our knowledge, the first 
study from a SA setting wherein a thorough description of characteristics in patients 
admitted to a tertiary-level healthcare facility with PE is given.  We also report several 
differences and similarities related to PE between SA and overseas populations.  
 
Demographic profile of the SP: 
 
Only a small proportion of patients in our SP were elderly.  Evidence from overseas 
settings suggests that the risk of VTE (including PE) increases with age.  An incidence 
of 2.0 per every 1000 persons per year was reported for patients up to 64 years old in 
the European study by Naess et al.(9)  The same study reported that the incidence of 
VTE increased to almost 8.0 per every 1000 persons per year in patients 65 years old or 
older.(9)  It therefore appears that our study finding for age contradicts the findings from 
studies of overseas populations.  It is possible that the interaction of various risk factors 
in the younger and older SA population might possibly explain this difference.  This 
would require further research to confirm.  Almost one in every three patients in our 
study population was female.  This finding is in agreement with much of the published 
literature from overseas settings which suggests a higher incidence of PE in females 
versus males.(10)  In vivo and ex vivo studies have shown a difference in platelet 
reactivity between males and females, specifically the formation of larger platelet 
aggregates in females, which offers a potential explanation for the gender disparity in 
PE.(10)  We found that the majority of patients with PE in our SP were of African 
ethnicity.  There might be two explanations for this finding.  Firstly, this finding might 
reflect the demographic profile of the South African population and the population 
served by our healthcare facility.(11,12)  Secondly, studies of American and European 
populations have also found persons of African ethnicity to be at a higher risk for VTE 
when compared to Caucasians (up to 40.0% higher risk).(13)  This appears to be linked to 
genetic polymorphism, as well as the burden of some VTE risk factors in the African 
ethnic group.(13)  A British study by Aylin et al., reported that only 2.1% of patients 
admitted to hospital for PE were elective admissions, with the remaining 97.9% of 
patients being non-elective/emergency admissions.(14)  In contrast to the study of Aylin 
and colleagues,(14) we report a much higher proportion of elective admissions (ie. 
Admissions route not the emergency department/critical care unit) versus non-
elective/emergency admissions (ie. Admissions route not the emergency 
department/critical care unit) for PE.  This seems to suggest much lower levels of 
critical illness/higher levels of chronic illness related to PE admissions in our setting 
when compared with overseas settings.                 
 
Symptoms and signs of PE in the SP: 
 
As with descriptions of PE in overseas settings, we report the presentation of PE to be 
highly variable in our setting.  There were several similarities and differences in the 
distribution of PE symptoms in our SP versus that described for overseas populations 
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with PE.  Chest pain and dyspnoea were the most common presenting symptoms in our 
SP, which is in agreement with the overseas literature.(3)  Both symptoms are reflective 
of the pathophysiological impact of PE on the cardiopulmonary system.(15)  However, 
we report a lower prevalence of pleuritic chest pain and a higher prevalence of 
substernal chest pain in our SP when compared to these descriptions of chest pain 
reported for overseas populations (24.6% versus 52.0% and 16.4% versus 12.0%, 
respectively).(3)  There was a slightly higher prevalence of dyspnoea in our study 
population when compared with that reported for overseas settings (86.9% versus 
80.0%).(3)  With regard to other presenting symptoms, there was also a higher 
prevalence of cough and haemoptysis in our SP when compared with evidence from 
overseas settings.  Lastly, the prevalence of syncopal events in our SP was lower than 
that reported for overseas populations with PE (14.7% versus 19.0%).(3)  Tachypnea and 
tachycardia were the most frequently encountered presenting signs in our SP.  This 
overall finding is once again in agreement with the overseas literature.  However, there 
were differences in the distribution of tachypnea and tachycardia between our SP and 
overseas populations.  When compared with the overseas literature, our study reports a 
lower frequency of tachypnea (47.5% versus 70.0%) and a higher frequency of 
tachycardia (42.6% versus 26.0%) in patients with PE.(3)  There was also a lower 
prevalence of cyanosis and pyrexia in our SP when compared with overseas populations 
(4.9% versus 11.0% and 3.3% versus 7.0%, respectively).(3)  However, we do report a 
higher prevalence of lower limb swelling/pain in our SP when compared with the 
overseas literature (37.7% versus 15.0%).(3)  The differences in the distribution of 
various symptoms and signs between our SP and overseas populations highlights the 
challenges that clinicians in different settings might face during initial attempts at 
diagnosing PE through clinical examination and patient medical histories.  Considering 
that there was a lower prevalence of many of the symptoms and signs described for PE 
in overseas settings in our SP, the suspicion of PE might be underestimated in SA 
settings if overseas characteristics are applied.   It is therefore important that further 
studies of PE are performed in order to identify associated symptoms and signs which 
are more relevant in SA settings.    
 
Other important aspects of clinical presentation: 
 
While abnormal pulse oximetry or arterial blood gas (pO2), and the requirement for 
supplemental oxygen or mechanical ventilation are not considered specific 
symptoms/signs of PE, their presence in patients with this condition is indicative of 
hypoxia.(16-18)  Our findings therefore suggest that hypoxia is frequent in SA patients 
with PE.  This would be in keeping with the proposed pathophysiological effects of 
PE.(15)  The majority of patients in our SP were normotensive.  This finding suggests 
that cardiac output was not significantly affected by PE in most of our SP, as 
haemodynamic instability in PE is usually a consequence of ventricular dysfunction and 
reduced cardiac output.(15)  As expected, the majority of patients with recorded d-dimer 
tests in our SP had elevated measurements of this analyte reported.  D-dimers are cross-
linked fibrin degradation products following fibrinolysis of a thromboembolism.(19)  A 
number of patients in our SP also had elevated cardiac troponin measurements.  As 
cardiac troponin is released into the circulation following myocardial injury,(20) we can 
deduce that myocardial necrosis/myocardial ischaemia also accompanied PE in some of 
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our patients.  This would also be in accordance with the proposed pathophysiological 
effects of PE on the pulmonary and systemic circulation.(15)    
 
Prevalence of PE risk factors in the SP: 
 
Many of the established risk factors for VTE cause the condition through one of the 
pathological pathways comprising Virchow’s triad, which includes blood flow stasis, 
endothelial dysfunction/damage, and hypercoagulation.(21)  As with the clinical 
symptoms and signs, we observed similarities and discrepancies in the distribution of 
established risk factors for PE between our SP and overseas populations.  The 
prevalence of cardiac failure and stroke in our SP was much higher than that reported 
for overseas populations (49.2% versus 8.2% and 3.3% versus 1.8%, respectively).(22) 
The proportion of patients with recent immobilization was similar in our SP and 
overseas populations with PE (13.1% versus 12.0%).(22)  The proportion of patients in 
our SP with recent long distance travel was also similar to that reported for overseas 
populations with thromboembolic disease (3.3% in our setting versus up to 3.9% in 
overseas settings).(23)  A higher proportion of our SP had undergone recent surgery 
when compared with overseas PE populations (16.4 versus 11.2%).(22)  The prevalence 
of recent trauma was similar between our SP and overseas PE populations (3.3% versus 
up to 3.7%), while the prevalence of malignancy in our SP was almost seven times 
lower than that reported for overseas populations with PE (3.3% versus 22.3%).(22)  
Smoking was less prevalent in our SP when compared with overseas settings (9.8% 
versus 30.5%).(24)  A history (current or prior) of venous thromboembolism was 8.2-
19.7% in our SP when compared with a reported 26.0% in overseas settings.(22)  Data 
from overseas settings show that there is a low prevalence of pregnancy in populations 
with PE (estimated prevalence of 1.1%).(22)  Our study reports no cases with pregnancy, 
which appears to be in accordance with the reported low prevalence in overseas settings.  
The prevalence of hormonal therapy/oestrogen use appears similar between SA and 
overseas settings (1.6% and 2.0%, respectively).(22)  Obesity is more prevalent in 
overseas populations with PE versus SA populations with this condition (37.8% versus 
27.9%).(22)   While HIV and tuberculosis have not been identified as potential 
comorbidities of interest in populations with PE in overseas settings,(3,22) recent 
evidence from SA has suggested that HIV and tuberculosis are amongst the most 
prevalent comorbidities in patients with DVT.(8)  Interestingly, we report a much lower 
prevalence of HIV and tuberculosis in SA patients with PE when compared with DVT 
patients from a similar setting (27.9% and 4.9-13.1% versus 51.9% and 35.8%, 
respectively).(8)  Our findings of discrepancies in the prevalence of PE risk factors 
between SA and overseas populations might have important implications for the initial 
diagnosis of PE in SA settings, as overseas management guidelines (which describe 
overseas risk factors) are often used in our setting.  Differences in the prevalence of PE 
risk factors between SA and overseas populations also important implications related to 
risk reduction initiatives for PE in SA settings.  Therefore, appropriate setting-specific 
studies of PE risk factors in SA patients are required.           
 
Classification and treatment of PE in the SP: 
 
The PE population in overseas settings is comprised of patients with massive PE, 
submassive PE, and minor PE in the following proportions: 5.0%, 40.0% and 55.0%, 
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respectively.(25)  Our findings suggest a slightly higher prevalence of massive PE, a 
much higher prevalence of submassive PE, and a much lower prevalence of minor PE in 
our SP when compared with overseas populations.  However, we report an overall 
finding of a lower prevalence of massive versus non-massive (submassive and minor) 
PE which is in keeping with the overseas literature.(25)  Almost two-thirds of our SP 
were classified as having submassive PE, with less than one in every ten patients 
classified as having massive PE according to currently accepted definitions, which are 
based on the presence/absence of haemodynamic instability and cardiac 
dysfunction/injury.(26)  The presence of haemodynamic instability is often a proxy for 
the degree of occlusion caused by a PE in the pulmonary circulation.(26)  We can 
therefore conclude that most patients with PE in our SA setting did not have more 
severe manifestations of PE with associated haemodynamic instability.  As in overseas 
settings,(26) anticoagulation therapy formed the backbone of PE treatment in SA 
patients.  Also in keeping with overseas management practices, intervention by 
thrombolysis or embolectomy was carefully considered in our setting and was only 
performed when there was a relevant indication to perform either of these 
interventions.(26,27)  It therefore appears that the management of PE in our SA setting is 
in accordance with overseas guidelines/recommendations. 
 
Mortality and associated characteristics in the SP: 
 
The incidence of inpatient mortality in our SP was within the range reported for 
overseas populations with PE (<1.0% to 60.0%).(28-31)  The majority of deaths in our SP 
were in patients who had submassive PE.  This suggests that in addition to PE with 
haemodynamic instability (ie. massive PE) which has traditionally been considered to 
account for most inpatient deaths in overseas settings,(25) PE in haemodynamically 
stable patients might be of concern in SA settings.  We found crude statistical 
associations between five of the patient/clinical characteristics investigated in our study 
and inpatient mortality, which included: admission through the emergency 
department/critical care unit, dyspnoea, tachycardia, and embolectomy.  As patients 
with acute PE are more likely to be admitted as non-elective/emergency cases,(31) our 
findings for hospital admission route suggest that acute PE is associated with increased 
mortality in SA patients.  The overseas literature also reports a high mortality rate (of up 
to 50.0%) in patients with acute PE.(32)  While there is no specific evidence from 
overseas settings reporting the association of dyspnoea grading on outcomes in patients 
with PE, our finding for dyspnoea is in agreement with prior reports of dyspnoea from 
general medical populations in overseas settings which show an almost three-fold 
increased risk of cardiovascular or all-cause mortality when compared with dyspnoea-
free populations.(33)  Similarly, there is no specific literature reporting the impact of 
tachycardia on mortality in patients with PE.  However, data from general populations 
in overseas settings have shown this clinical sign to be associated with a higher risk of 
morbidity and mortality,(34) which our findings appear to mirror.  Pulmonary 
embolectomy has traditionally been associated with high mortality rates of up to 32.0% 
in overseas settings.(35)  It is therefore no surprise that we observed increased mortality 
in patients who underwent pulmonary embolectomy versus patients who did not 
undergo this high-risk surgical procedure.   
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We did not observe statistically relevant associations between the other characteristics 
investigated in our study and inpatient mortality.  There are two possible explanations 
for this.  Firstly, it might be that these characteristics are genuinely not associated with 
mortality in SA patients with PE.  Secondly, it could be that our modest sample size did 
not allow for weaker statistical associations between these characteristics and inpatient 
mortality to be detected.  Nevertheless, we report on the characteristics which had the 
strongest statistical associations with inpatient mortality in our study.     
 
Strengths and limitations of our study: 
 
A strength of our study is that we provide an in-depth description of the presentation, 
risk factor prevalence, treatment, and outcome in patients with PE from a SA setting.  
As previously mentioned, reports of PE from African settings are rare.  A limitation of 
our study is that our modest sample size prevented us from performing further statistical 
investigations of characteristics associated with inpatient mortality in our SP.  Another 
limitation of our study is that our study population was from a single, tertiary-level 
healthcare facility.  Therefore, our study findings might not be applicable to SA patients 
with PE attending lower-level healthcare facilities.  Data was missing for some 
characteristics, however we did not exclude patients with missing data from our analysis 
and accounted for missing data with the “not reported” category.  Finally, we only 
report on inpatient outcomes and we do not report patient outcomes following discharge 
from hospital.  Large, multicentre, prospective studies are required to address these 
study limitations.       
 
Conclusion: 
 
We provide a report of the presentation, risk factor prevalence, treatment, and outcomes 
of PE in SA patients.  There were several differences and similarities between the 
presentation and prevalence of risk factors associated with PE in SA and overseas 
settings.  This has potentially important implications with regard to the initial diagnosis 
of PE in SA patients, as well as potentially important implications related to risk 
stratification in SA patients with PE.  Treatment of SA patients with PE is in line with 
that recommended in overseas management guidelines.  Inpatient mortality in SA 
patients with PE was in the range reported for overseas populations with PE.  Further 
research is required to confirm our findings, as well as to address the limitations of our 
study.   
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BACKGROUND 
Pulmonary embolism (PE) is amongst the most important complications of deep vein 
thrombosis (DVT).1  Specifically, pulmonary embolism results from the migration of a 
thrombus in the lower limbs to the lung.2,3  The thrombus may then cause occlusion of 
the pulmonary circulation which has adverse consequences on pulmonary and cardiac 
function.3  Both DVT and PE are manifestations of thromboembolic disease.1  The 
incidence of PE in overseas settings is estimated at 1.0 case per 1000 people.4  Early 
mortality rates in patients with PE are high.  It is reported to account for 5-10% of all 
inpatient deaths.5  The presentation of PE is varied and can pose diagnostic 
challenges.2,4,5  The mortality rate is much higher in patients with undiagnosed, 
untreated PE and this highlights the importance of understanding the clinical and 
biochemical presentation of PE such that patients can be diagnosed timeously and 
treatment can be initiated.5   
 
South Africa is currently experiencing an epidemiological transition, whereby the 
national noncommunicable disease burden is approaching that of communicable 
disease.6  Non-communicable diseases comprised 60% of the ten leading underlying 
natural causes of death in South Africa for 2015.7  While no specific data is available 
for PE, a 2007 report found 2566 deaths in the country could be attributed to diseases of 
the circulatory system, a composite measure which includes PE, stroke, and myocardial 
infarction.8  Interestingly, embolic pathophysiology also appears to play some role in 
stroke and myocardial infarction.9,10  However, descriptions of PE in South African 
settings are rare.  Recent evidence from a study of DVT in a South African setting 
suggest that there are some setting-specific risk factors for thromboembolic disease, 
most notably HIV infection and tuberculosis.11  It is also possible that there might be 
some discordancy between clinical/biochemical presentation and risk factors for PE 
between South African settings and European/American settings, however this is yet to 
be demonstrated.  It might also be possible that there are differences in mortality 
between South African and overseas patients with PE.  A better description of PE in a 
South African setting would be useful in efforts to improve patient management and 
subsequent patient outcomes in this setting.    
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AIM 
The aim of this study will be to improve the current understanding of PE in a South 
African setting. 
 
OBJECTIVES 
The objectives of this study will be 
1. Describe the presentation of PE in patients who were admitted to a tertiary South 
African hospital with the condition (the study population) 
2. Determine the incidence of mortality in the study population 
3. Determine which presenting characteristics are associated with inpatient mortality in 
the study population   
 
METHODS 
Study design, study setting, and study population: 
This will be a retrospective case series of adult (≥18 years old) patients who were 
admitted to the tertiary-level Inkosi Albert Luthuli Central Hospital (IALCH) in 
Durban, South Africa between over a 5-year period (2011-2015) with a primary 
diagnosis of PE.  Briefly, the hospital admissions database will be screened for all 
patients with a primary diagnosis of International Classification of Diseases 10th 
Revision (ICD-10) code I26 (includes I26.0 and sub-categories and I26.9 and sub-
categories).  Specific inclusion and exclusion criteria for this study are provided in 
Table 1. 
 
Table 1.  Inclusion and exclusion criteria for the proposed study 
Inclusion Criteria Exclusion Criteria 
Patients aged 18 years or older Patients younger than 18 years old 
Patients who were admitted for PE at 
IALCH between 01 January 2011 and 
31 December 2015 
Patients who were not admitted for PE at 
IALCH between 01 January 2011 and 31 
December 2015 
Patient not previously included in study Patient previously included in study 
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Sample size: 
As descriptive statistics for a case series do not involve direct statistical comparisons 
between groups (ie. There is no comparator group – all patients have PE),12 our 
minimum sample size will be based on the planned mortality analysis (study objective 
3) where there will be comparisons made between two groups (patients who died and 
patients who did not die).  This will involve a chi-squared statistical test.  The rule of 
thumb minimum sample size for a chi-squared test is 20 patients.13  As PE is rarely 
encountered, we estimate that there will be between 60 and 100 patients who were 
admitted to the hospital with PE as a primary diagnosis over the five year study period 
(out of all patients admitted to hospital during the study period). All these patients will 
be included in our study.  Therefore our projected sample size exceeds the rule of thumb 
sample size for a chi-squared test, and will be sufficient for our case series study design. 
 
Data collection: 
The electronic medical records of all eligible patients will be reviewed and data related 
to various patient characteristics/other comorbidity, clinical and laboratory presentation 
at admission, treatment, and inpatient mortality will be collected using a data collection 
form (Appendix 1).   These variables have been identified in the published literature as 
potentially important with regard to PE.2,4,14  In addition, we will collect data related to 
HIV infection and tuberculosis as these have been shown to be associated with deep 
vein thrombosis (an established risk factor for PE) in a South African setting.11  All data 
will then be transferred from the data collection forms to a de-identified, password 
protected database compatible with a statistical software package. 
 
Statistical analysis: 
We will conduct a descriptive analysis of data for variables collected in Appendix 1.  
Some variables may be dichotomized or categorized in order to facilitate our planned 
statistical analyses.  These categories will be based on meaningful definitions obtained 
from the published literature.  Results for the descriptive analysis will be presented as 
frequencies and percentages.  The incidence of inpatient mortality will be determined 
using standard epidemiological methods.15   
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In addition, crude associations between various aspects of PE clinical/laboratory 
presentation and inpatient mortality will be investigated using a chi-squared test.  
Results from this crude statistical analysis will be presented as frequencies (with 
percentages) in each group, and a corresponding p-value.  A p-value <0.050 will be 
considered statistically significant.  All statistical analyses will be performed using the 
Statistical Package for the Social Sciences version 24.0 (IBM Corp, USA).    
 
Ethical approval: 
This is a sub-analysis of data being collected as part of a larger study of hospital 
admissions, inpatient outcomes, and quality improvement at IALCH which has already 
received approval from the University of KwaZulu-Natal Biomedical Research Ethics 
Committee (BE595/16). Approval/a waiver from the University of KwaZulu-Natal 
Biomedical Research Ethics Committee will still be sought prior to commencing this 
specific sub-analysis. 
 
POTENTIAL IMPACT OF RESEARCH 
This study will provide important information which will allow for improved 
management of South African patients with PE.  We believe that the South African 
setting is unique in regards to patients who may suffer pulmonary embolism. Patient 
demographics, medical comorbidities and heightened risk factors are all variables which 
contribute to a differing subset of patients previously described in western literature or 
in developed-world settings.  As such, we believe, this study can contribute to 
determining the additional factors to be considered in suspecting, diagnosing and 
ultimately treating patients with pulmonary embolism in our setting. 
 
DISSEMINATION OF STUDY RESULTS 
The results of this research will be made available to the scientific community through 
publication in an accredited, peer-reviewed medical journal. The results of the research 
will also be reported to the KwaZulu-Natal Department of Health. A lay summary of the 
results will also be made available on selected print and electronic media. 
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PROPOSED WORK PLAN (WITH REFERENCE MAY 2017- MAY 2018) 
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Submit proposal to ethics and 
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APPENDIX 1:   PULMONARY EMBOLISM STUDY (Data collection form) 
Participant Study Number (For office use only): ____________________________ 
 
PATIENT DEMOGRAPHICS & ADMISSION ROUTE 
1.  Age in years:_____________  
2.  Gender (Male/Female): _________________ 
3.  Ethnicity: ________________________ 
4.  Admitted through emergency department/critical care unit (Y/N): __________ 
 
SYMPTOMS AT TIME OF ADMISSION 
1.  Dyspnoea – If “Y”, NYHA grade or grade not reported (Y/N): ________________ 
2.  Chest pain – if “Y”, pleuritic/substernal/nature not reported (Y/N):_______________ 
4.  Cough (Y/N): ______________________ 
5.  Haemoptysis – if “Y”, specify minor/major/nature not reported (Y/N):___________ 
6.  Syncopal event – if “Y” specify syncope/presyncope (Y/N): ___________________ 
7.  Massive PE – Acute PE and secondary hypotension with no other cause of 
hypotension other than PE (Y/N): __________ 
 
SIGNS AT TIME OF ADMISSION 
1.  Tachypnoea >20 breaths per min (Y/N): __________________________ 
2.  Tachycardia >100 beats per min  (Y/N):  _________________________ 
3.  Cyanosis (Y/N):  _________________________ 
4.  Temperature >38.5oC (Y/N): __________________ 
5.  Lower limb swelling/pain (Y/N): __________________ 
 
OTHER IMPORTANT SIGNS/VITALS AT TIME OF ADMISSION 
1.  O2 saturation (%): ________________ 
2.  pO2 from arterial blood gas test (mmHg): _________________ 
3.  Supplemental O2 (Y/N): __________ 
4.  Mechanical ventilation (Y/N): __________ 
5.  Systolic blood pressure (mmHg):   ________________ 
6.  Diastolic blood pressure (mmHg):  ________________ 
 
PRE-ADMISSION RISK FACTORS 
1.  Systemic Hypertension (Y/N):  ____________________________ 
2.  Immobilization of three days or more within last 4 weeks (Y/N):  ______________ 
3.  Long distance travel (more than four hours) within last 4 weeks (Y/N): ___________ 
4.  Surgery within last four weeks – list procedure if Yes (Y/N): __________________ 
5.  Trauma within last four weeks (Y/N):  ____________________ 
6.  Malignancy – haematologic or solid if Yes (Y/N): _______________________ 
7.  Tobacco use(Y/N): __________________________ 
8.  Cerebrovascular disease – stroke or TIA (Y/N): _______________ 
9.  History of previous PE or DVT (Y/N):  _______________________ 
10.  Heart failure (Y/N):  ____________________ 
11.  HIV infection (Y/N):  ____________________ 
12.  Current pregnant state (Y/N): ______________________ 
13.  Hormone replacement therapy/hormonal contraception (Y/N): _______________ 
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14.  Current tuberculosis infection (Y/N):  ____________________ 
15.  Obesity – Body mass index>30 kg/m2 (Y/N): ______________________ 
 
LABORATORY FINDINGS ON ADMISSION 
1.  Quantitative D-dimer (μg/L):  ______________________ 
2.  Cardiac enzymes (Specify Troponin or CKMB and respective units):_____________ 
 
TREATMENT WHILE ADMITTED 
1. Anticoagulation eg. Heparin, enoxaparin, warfarin (Y/N): ___________________ 
2. Thrombolysis (Y/N): _________________________ 
3.  Pulmonary embolectomy (Y/N): _________________ 
  
INPATIENT OUTCOME 
1.  Mortality (Y/N): __________________ 
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Appendix 2:  Journal guidelines  
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Appendix 3:  Study approvals  
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